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Chapter r
In Chapter I an introduction on herpesviruses and type-specific serology is given
Herpes simplex virus (HSV) is one of the besrstudied herpesviruses. Despite this
many of its properties are still unknown. Herpesviruses are present in a large part o
the population and it is common that infected individuals transmit the virus withou
knowning that they are infected. After a primary infection herpesviruses becomr
latent and latency lasts lifelong. During latency, the virus can be reactivated from itr
latent state and give recuÍrences or reactivations. The recuÍrences can be symptomatic
or asymptomatic and during both episodes virus shedding can occur. HSV-l used tc
be a pathogen of orolabial herpesvirus infections and HSV-2 used to be a pathogen ol
genital herpesvirus infections. Recently HSV-l was found to be associated witl
genital infections and HSV-2 was found in the oral region. With serological screenin;
HSV-l and HSV-2-infected individuals can be detected by the presence of HSV type-
specific antibodies. Virus detection as diagnostic tool for identification of the infectec
individuals is only possible during the acute phase of an active infection. Detection ol
type-specific antibodies has been hampered in the past by the extensive serologica
cross-reactivity between HSV-l and HSV-2. At present, commercial assays an
available (Chapter l), based on the type-specific antigens gG-l and gG-2 and thel
can be used for the detection of HSV-1 and HSV-2 type-specific antibodies.
The determination of the seroprevalence of HSV-2 and HSV-I in definec
populations in Groningen was the main aim of the study described in this thesis
Commercial assays are expensive because of the high costs of antigen preparation
Therefore their use in large-scale surveys is limited. As a solution to the cost aspects
we developed an "in house" assay by cloning of the type-specific glycoproteins G-l
and G-2 (Chapter 2). We used the baculovirus expression system, which is easy anc
safe to work with and convenient to produce relatively large amounts of proteins. We
started cloning of the complete sequence of gG-2 and a truncated version of gG-2
resulting in recombinant baculoviruses that expressed very little gG-2. In addition
these recombinant viruses were not stable. Therefore, we decided to clone a smaller
fragment of the gG-2 sequence, coding for amino acid residues 281-594. The latter
fragment contains most of the known epitopes of gG-2 and the proposed cleavage
sites that allow processing. In order to improve the expression, the gG-2 signa
sequence was replaced by the honeybee mellitin signal sequence. Six histidines wen
added to the C-terminus to allow purification by affinity chromatography. In addition
gG-l  (residues 26-189, gG-lp6-16e111.),  and gD-l  (residues l-313, gD-11-j11) were
cloned in the baculovirus expression system. The production of recombinant gG-2usr
-5e,+Hi. andgG-1t26-rasHis was confirmed by Western blot using type-specific monoclona
antibodies (MAbs, API and LPIO, respectively) and specific human sera. Tht
molecular masses of the major products of gG-1126-r8eHis and the fragment of gG-22s1
se+ui. were 36-39 kDa and 64-72 kDa, respectively. Human sera positive for HSV-
reacted with gG-1,26-r8eHis, sera positive for HSV-Z reacted with the gG-22u5saH;
fragment, and sera positive for both types reacted with gG-lt2o-resHis and gG-22s1-5eas,
in Western blot. The human sera recognized polypeptides of gG-22il-5eas1. witl
molecular masses of 57 -61 and I 20- 150 kDa and additional faint bands of 2l . 29. anr
45 kDa. The recombinant gG-1,20-rsqHis &ndthe recombinant gG-22s1-5eas;. fragmen
were used as type-specific antigens for the detection of HSV-l and HSV-2 specifi,
antibody responses in human sera, respectively. As type-common antigens, an extrac
of HSV-l infected Vero cells and recombinant gD-11-313 wete used. An ELISA to
detect type-specific antibodies was developed and the sensitivity and specificity were
evaluated by comparison with commercial tests using sera obtained from different
sources. The sensitivity and specificity were 9l .5 7o and 95.5 7o, respectively,
compared to the first version of the Gull assay as it was distributed by GULL
Laboratories, Meridian Bioscience, Inc. Cincinnati, USA. The gG-22s1-rr+ui. fragment
could be obtained in relatively large quantities at low cost.
After we had developed this ELISA for the detection of HSV-I and HSV-2 type-
specific antibodies, it became possible to perform follow-up studies and to investigate
whether antibody titers against different antigens derived from HSV change over time
(Chapter 3). To this end, we analyzed the follow-up sera of HSV isolation-positive
patients who attended the outpatient STD clinic of the Municipal Health Service
(GG/GD), Amsterdam. We used 4 antigens i.e., the extract of HSV-l infected cells
and baculovirus-expressed gD-l (gD-l ' lr:) as type-common antigens, and
baculovirus-expressed gG-l (gG-1,26-r8eHis) and a fragment of gG-2 (gG-228r-5e4His) as
type-specific antigens for the determination of antibodies. Among 145 genital HSV
culture-proven patients, HSV-l was isolated from 30 patients (20.7Eo). Twenty of
them had only antibodies against HSV-1. The number of women (30o/o) with genital
HSV-1 infect ionswassignif icant lyhigherthanthenumberof men (127o) withgenital
HSV-I infections (p= 0.008). Follow-up sera were available of 103 out of 145
patients. Based on the virus isolation together with serological data of the follow-up
sera, the patients were diagnosed as having primary infections, nonprimary initial
infections, and recurrences at the time of visit to the clinic. Fifteen patients had
primary infections, 4 patients had nonprimary initial infections, and 84 patients had
recuÍrences. Antibodies against HSV and/or gD appeared earlier or at the same time
as antibodies against gG-l and gG-2. Except for in 5 patients (4 had a primary and I a
recurrent infection) whose antibodies against HSV and gG were present earlier than
the antibodies against gD. The mean antibody titer to HSV in HSV-I isolation
positive patients was 2484 and 6140 in HSV-2 isolation positive patients. The mean
gD titers were 1817 in HSV-1 isolation positive patients and 5030 in HSV-2 isolation
positive patients. The mean gG-l titer was 628 in HSV-l isolation positive patients
and64l in HSV-2 isolation positive patients. The mean gG-2 titers were 4ll in HSV-
1 isolation positive patients and 694 in HSV-2 isolation positive patients. Each mean
titers were higher in HSV-2 isolation positive patients.
Among l5 patients with primary infections, all developed antibody titers against
HSV but I and 4 patients did not develop antibodies against gD and gG respectively.
The nonprimary infected patients had antibodies against HSV gD, gG-l and gG-2.
Two of them lost type-specific antibodies against gG. One of the two had changes in
HSV, gD and gG-l antibody titers as well. Of the 84 patients with recurrent infections
47 had stable antibody titers against HSV gD and gG. Twelve of the patients with
recurrent infections did not develop gG type-specific antibodies. Changing antibody
titers were found in l3 patients, 5 of which were among the twelve patients that did
not develop gG type-specific antibodies at the time of virus isolation. Four patients
with recunent infections lost type-specific antibodies, two of them were among the
l3 patients with changes in antibody titers. It was clearly demonstrated that in HSV-l
and HSV-2 isolation positive genital herpes patients changes in antibody titers and
sometimes loss of type-specific antibodies may occur over time.
Next, the HSV-1 and HSV-2 seroprevalence in two defined populations, the STD
clinic attenders of the Department of Dermatology in Groningen, and a population of
women with dyskaryotic smears at risk for cervical cancer, attending the
Gynaecology Department, also from the University Hospital in Groningen, were
determined.
For determination of the HSV-l and HSV-2 prevalence of STD clinic attenders,
samples were collected from the patients who were admitted to the hospital and
requested screening for STDs, mainly for syphilis and/or HIV infections (Chapter 4).
A total of 493 serum samples was investigated. The samples were collected from
October 1996 to May 1998 at the STD clinic of the Department of Dermatology of
the University Hospital Groningen, The Netherlands. The overall seroprevalence of
HSV-l and HSV-2 in the STD clinic attenders was 70.07o and lJ.27o, respectively.
The seroprevalence of HSV-1 was higher in males and the HSV-2 seroprevalence was
higher in females. Both HSV-l and HSV-2 seroprevalence was significantly higher in
the population of non-Dutch origin. The seroprevalence of HSV-2 was significantly
higher in the populations who had current other STDs, i.e. HIV positive and syphilis
positive patients. The seroprevalence of HSV-l and HSV-2 was significantly higher
in the population with a history of STD. Homosexual and bisexual orientation was
associated with HSV-1 and HSV-2 seropositivity. The acquisition of HSV-2
antibodies occurred at younger age in females than in males. The STD clinic has a
policy that testing is performed anonymously on patients' requests. Out of 493
patients 120 (24.37o) requested anonymous testing. Among those 120 patients, the
HSV-l and HSV-2 seroprevalence was significantly higher in females than that in
males (807o versus 56.47o,27.7Vo versus 5.57o, respectively). The seroprevalence of
HSV-2 of the STD clinic attenders in Groningen was slightly lower but similar to the
HSV-2 seroprevalence in other STD groups, i.e. Rotterdam, The Netherlands.
The second population of which the seroprevalence of HSV-l and HSV-2 was
determined was a group of 296 women with dyskaryotic smears at risk for cervical
cancer (Chapter 5). Serum samples from 296 women with dyskaryotic smears were
collected and screened for the presence of HSV-l and HSV-2 antibodies by our type-
specific "in house" ELISA. The recruited women responded to a questionnaire with
regard to age of first pregnancy, age of first sexual intercourse, smoking habits,
lifetime number of sexual partners, oral contraception use, history of sexually
transmitted iseases (STDs), fever blisters, and (peri-) vulval warts to analyze risk
factors associated with HSV seropositivity. The seroprevalence of HSV-l and HSV-2
infections in this population was 89.9Vo and 38.5Va, respectively. HSV-l
seropositivity was relatively high when compared with female STD clinic attenders,
and was associated with seropositivity for Chlamydia trachomatis (C. trachomatis).
Several studies have indicated an increasing incidence of genital herpes caused by
HSV-I. This has been attributed to "changes in sexual practice" together with a
decrease of HSV-l infections in childhood. In our study, the HSV-1 seropositivity in
the women with dyskaryotic smears was significantly associated with the presence of
antibodies against C. trachomatis, which linked HSV-l seropositivity to the
occuÍrence of one of the most frequent STDs. When more stringent statistics (method
of Bonferroni) were applied, the association of HSV-l seropositivity and the presence
of antibodies against C. trachomaris did not remain. The seroprevalence of HSV-2 in
women with dyskaryotic smears is relatively high as well for the geographic area of
Groningen, where in Dutch female STD attenders a relatively low HSV-2
seroprevalence of 12.07o was found. The high HSV-2 prevalence in women with
dyskaryotic smears cannot be explained by any of the known risk factors for the
presence of HSV-2 antibodies.
Understanding of the HSV-l and HSV-2 seroprevalence in the above-mentioned
populations together with the already known data of the HSV-I and HSV-2
seroprevalence in The Netherlands can provide information to decide whether
effective prevention programmes are required for genital herpes in particular and for
STD populations in general.
